These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 23223392)

  • 1. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment.
    Sandström M; Garske-Román U; Granberg D; Johansson S; Widström C; Eriksson B; Sundin A; Lundqvist H; Lubberink M
    J Nucl Med; 2013 Jan; 54(1):33-41. PubMed ID: 23223392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of calculation method on kidney dosimetry in
    Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
    Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized
    Del Prete M; Buteau FA; Beauregard JM
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective observational study of
    Garske-Román U; Sandström M; Fröss Baron K; Lundin L; Hellman P; Welin S; Johansson S; Khan T; Lundqvist H; Eriksson B; Sundin A; Granberg D
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):970-988. PubMed ID: 29497803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney dosimetry during
    Sandström M; Garske-Román U; Johansson S; Granberg D; Sundin A; Freedman N
    Acta Oncol; 2018 Apr; 57(4):516-521. PubMed ID: 28920501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dosimetry procedure for organs-at-risk in
    Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
    Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
    Forrer F; Krenning EP; Kooij PP; Bernard BF; Konijnenberg M; Bakker WH; Teunissen JJ; de Jong M; van Lom K; de Herder WW; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1138-46. PubMed ID: 19247653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 10. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course.
    Bergsma H; Konijnenberg MW; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Franssen GJ; van Eijck CH; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):453-63. PubMed ID: 26419852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in
    Hagmarker L; Svensson J; Rydén T; Gjertsson P; Bernhardt P
    Cancer Biother Radiopharm; 2017 Nov; 32(9):335-343. PubMed ID: 29125780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [
    Blakkisrud J; Peterson AB; Wildermann SJ; Kingkiner G; Wong KK; Wang C; Frey KA; Stokke C; Dewaraja YK
    J Nucl Med; 2024 May; 65(5):753-760. PubMed ID: 38548350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
    Gupta SK; Singla S; Thakral P; Bal CS
    Clin Nucl Med; 2013 Mar; 38(3):188-94. PubMed ID: 23412597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
    Garkavij M; Nickel M; Sjögreen-Gleisner K; Ljungberg M; Ohlsson T; Wingårdh K; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1084-92. PubMed ID: 20127957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry and pharmacokinetics of [
    Schürrle SB; Eberlein U; Ansquer C; Beauregard JM; Durand-Gasselin L; Grønbæk H; Haug A; Hicks RJ; Lenzo NP; Navalkissoor S; Nicolas GP; Pais B; Volteau M; Wild D; McEwan A; Lassmann M
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
    J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
    Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
    J Nucl Med; 2024 Jun; 65(6):923-930. PubMed ID: 38637144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.